Company background
Pacific Software, Inc. (OTC Pink: PFSF)
Sectors: Skin Care, Wound Care and Medical Aesthetics
Industry: Cosmetics
Pacific Software, Inc. (PFSF), has recently emerged from its dormant status and last year jettisoned its prior business activities to purchase certain business assets from DREAMADERM Inc. a cosmeceutical, skincare and medical aesthetics company. PFSF a Nevada Corporation, recently filed the required financial statements with the OTC Markets for the period ended December 31, 2023. In addition a new Board of Directors and experienced management was appointed to lead DREAMADERM Inc. into the commercialization and distribution of it's suite of unique product combinations in the Cosmetics, Skincare and Medical Aesthetics sectors globally.
Investment Opportunities
TRACTION AND TIMELINE
.png)
Funding & Investment Opportunity
The company expects to access the capital markets in order to fund its projected business model as referenced in its five (5) year pro forma data included in DREAMADERM's investor deck presentation through various financial instruments and equity.
DREAMADERM’s assets were purchased on 1-23-2024 by OTC Markets-listed Pacific Software (PFSF) doing business as DREAMADERM until the name is changed. The company is actively pursuing $2 – 5M in debt and/or equity funding.
Financial
Initial Capital Raised $2-5M
Parthnerships
IPC licencing
C-suite
KOLS
5 Year Projections
Financials
Our strategic Partners
Our initial partnerships have been established through long standing relationships that have endured the tests of time. As we stretch out globally, we will continue to build these partnerships around global:
UCI Beall Applied Innovation
Grant Acquisition
Lab Incubator
Vitallia
Salud Esmeralda USA
MX Master Distributor/ Packaging
Colonial Dames USA
Master Formulation
Bulk Manufacturing/USA Distribution
University of California, Irvine
Patent Holdings
Equity Partner
National Healthcare Union of Mexico
Clinical Trials Facilitator
Relationship Mkt/Distribution
REJIMUS
Regulatory Guidance
Strategies Compliance
Our Team
Meet The Team
Harrysen Mittler
CEO / Chairman
Harrysen Mittler Brings over three decades of expertise in corporate finance mergers, acquisitions and business administration to the company. A Deloitte & Touche LLP alumnus, he served in the audit division and has held senior management and directorship positions with several emerging growth companies. Active as Chairman and CEO of Pacific Software Inc. he was instrumental in the development of innovative enterprise solutions internationally. His leadership extended to Grand Prix Sports Inc., a publicly quoted company, where he lead the operations as Chairman and CEO of a motor sports team which performed in the internationally acclaimed Formula 1 support auto racing Circuit. He also served as CFO of Nortia Capital Partners, a merchant bank where international and domestic ventures were developed and capitalized.
Jim DiPrima
CFO
Mr. DiPrima holds a B.S. in Business Administration from Creighton University and boasts 45 years in finance and accounting. Starting at Deloitte & Touche, he's held roles in start-ups, served as a manufacturing company's comptroller, and founded a medical-focused accounting firm. As CEO of MBD Midwest, he expanded pack and ship franchises across states. He was the founder and President of a construction firm serving the US Postal Services and has been with publicly traded firms since 1995. His expertise includes guiding reverse mergers, capital raising, and mezzanine financing consultations. Recently, he served as CFO for GBX International Group and Solar Integrated Roofing, and as CEO for PAO Group in the medical cannabis sector.
Dr. Jacqueline Jacques
Consultant
Dr. Jacqueline Jacques is a seasoned executive and entrepreneur merging expertise in medicine and industry, particularly in the medical nutrition and wellness sectors. Known for bridging gaps to drive organizational growth, Jacqueline has a rich history with startups, IPOs, M&A, product development, and global expansion. Currently, she’s a sought-after industry consultant, aiding a spectrum of clients from biotech startups to multinational ingredient suppliers in innovation and strategic growth. Previously, as the Chief Research Officer at Thorne Health Tech for nine years, she steered portfolio innovation and strategic acquisitions, fuelling over 20% YoY growth and elevating sales to nearly $300M. Her leadership was pivotal in Thorne’s 2021 IPO.